A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 476-481

  Chauzit, Emmanuelle ^a   Bouchet, Stéphane ^a   Micheau, Marguerite ^a   Mahon, François Xavier ^a,b   Moore, Nicholas ^a,b,c   Titier, Karine ^a   Molimard, Mathieu ^a,b,d  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM U876   (France)

^d INSERM U657   (France)

Author keywords

chromatography; deferasirox; iron overload; mass spectrometry; therapeutic drug monitoring

Indexed keywords

ACETONITRILE; DEFERASIROX; DEFERASIROX GLUCURONIDE; FERRITIN; FORMIC ACID; GLUCURONIDE; ILC 670 A; METHANOL; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; SOLVENT; TRIAZOLE DERIVATIVE;

ACUTE LEUKEMIA; ARTICLE; BLACKFAN DIAMOND ANEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FERRITIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; PRECIPITATION; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; SICKLE CELL ANEMIA; TANDEM MASS SPECTROMETRY; THALASSEMIA; BLOOD; BLOOD SAMPLING; CALIBRATION; DOSE RESPONSE; QUALITY CONTROL; REPRODUCIBILITY; STANDARD;

BENZOATES; BLOOD SPECIMEN COLLECTION; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 77955177294     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d8b37f     Document Type: Article

References (25)

1. Rose C.Post transfusionnal iron overload. Rev Prat. 2006;56:2141-2145.
2. McCullough KD, Bartfay WJ. The dose-dependent effects of chronic iron overload on the production of oxygen free radicals and vitamin E concentrations in the liver of a murine model. Biol Res Nurs. 2007;8:300-304.
3. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl 3):S2-S6.
4. Borgna-Pignatti C, Rugolotto S, Cappellini MD, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
5. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114-117.
6. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411-3416.
7. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007;138:407-421.
8. Sechaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther. 2008;46:102-108.
9. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565-572.
10. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-880.
11. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91:1343-1351.
12. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43-47.
13. Rouan MC, Marfil F, Mangoni P, et al. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;755:203-213.
14. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily loaded patients with beta-thalassemia. Eur J of Haematol. 2009;82:4.
15. Bressolle F, Bromet-Petit M, Audran M. Validation of liquid chromato-graphic and gas chromatographic methods Applications to pharmacoki-netics. J Chromatogr B Biomed Sci Appl. 1996;686:3-10.
16. Causon R. Validation of chromatographic methods in biomedical analysis viewpoint and discussion. J Chromatogr B Biomed Sci Appl. 1997;689: 175-180.
17. Nicolas O, Farenc C, Bressolle F. A strategy for validation of bioanalytical methods to support pharmacokinetic and toxicological studies. Ann Toxicol Anal. 2004;XVI:10.
18. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Secondary Food and Drug Administration, Editor. Rockville, MD: Center for Drug Evaluation and Research; 2001.
19. Viswanathan C, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromato-graphic and ligand binding assays. Pharm Res. 2007;24:1962-1973.
20. Annesley TM. Ion Suppression in mass spectrometry. Clin Chem. 2003; 49:1041-1044.
21. Muller, C, Schafer P, Stortzel M, et al. Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J Chromatogr B Anal Technol Biomed Life Sci. 2002. 773:47-52
22. EMEA. European Public Agreement Report on Deferasirox. London: European Medicines Agency; 2006:1-52.
23. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacoki-netics in patients with adequate vs. inadequate response. Blood [online]. 2009: blood-2009-05-222729. Available from: http://bloodjournal.hema-tologylibrary. org/. Accessed September 1, 2009.
24. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-3462.
25. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-508.